The nonapeptide vasopressin acts both as a hormone and as a neurotransmitter/neuromodulator. As a hormone, its target organs include kidney, blood vessels, liver, platelets and anterior pituitary. As a neurotransmitter/neuromodulator, vasopressin plays a role in autonomic functions, such as cardiovascular regulation and temperature regulation and is involved in complex behavioral and cognitive functions, such as sexual behavior, pair-bond formation and social recognition. At the neuronal level, vasopressin acts by enhancing membrane excitability and by modulating synaptic transmission. The present review will focus on the electrophysiological effects of vasopressin at the cellular level. A large proportion of the experiments summarized here have been performed in in vitro systems, especially in brain and spinal cord slices of the rat. Vasopressin exerts a powerful excitatory action on motoneurons of young rats and mice. It acts by generating a cationic inward current and/or by reducing a potassium conductance. In addition, vasopressin enhances the inhibitory synaptic input to motoneurons. By virtue of these actions, vasopressin may regulate the functioning of neuronal networks involved in motor control. In the amygdala, vasopressin can directly excite a subpopulation of neurons, whereas oxytocin, a related neuropeptide, can indirectly inhibit these same neurons. In the lateral septum, vasopressin exerts a similar dual action: it excites directly a neuronal subpopulation, but causes indirect inhibition of virtually all lateral septal neurons. The actions of vasopressin in the amygdala and lateral septum may represent at least part of the neuronal substrate by which vasopressin influences fear and anxiety-related behavior and social recognition, respectively. Central vasopressin can modulate cardiovascular parameters by causing excitation of spinal sympathetic preganglionic neurons, by increasing the inhibitory input to cardiac parasympathetic neurons in the nucleus ambiguus, by depressing the excitatory input to parabrachial neurons, or by inhibiting glutamate release at solitary tract axon terminals. By acting in or near the hypothalamic supraoptic nucleus, vasopressin can influence magnocellular neuron activity, suggesting that the peptide may exert some control on its own release at neurohypophyseal axon terminals. The central actions of vasopressin are mainly mediated by receptors of the V(1A) type, although recent studies have also reported the presence of vasopressin V(1B) receptors in the brain. Major unsolved problems are: (i) what is the transduction pathway activated following stimulation of central vasopressin V(1A) receptors? (ii) What is the precise nature of the cation channels and/or potassium channels operated by vasopressin? (iii) Does vasopressin, by virtue of its second messenger(s), interfere with other neurotransmitter/neuromodulator systems? In recent years, information concerning the mechanism of action of vasopressin at the neuronal level and its possible role and function at the whole-animal level has been accumulating. Translation of peptide actions at the cellular level into autonomic, behavioral and cognitive effects requires an intermediate level of integration, i.e. the level of neuronal circuitry. Here, detailed information is lacking. Further progress will probably require the introduction of new techniques, such as targeted in vivo whole-cell recording, large-scale recordings from neuronal ensembles or in vivo imaging in small animals.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.ejphar.2007.11.074 | DOI Listing |
Resusc Plus
January 2025
Centre for the Studies of Asphyxia and Resuscitation, Neonatal Research Unit, Royal Alexandra Hospital, Edmonton, Alberta, Canada.
Background: Epinephrine is currently the only recommended cardio-resuscitative medication for use in neonatal cardiopulmonary resuscitation (CPR), as per consensus of science and treatment recommendations. An alternative medication, vasopressin, may be beneficial, however there is limited data regarding its effect on cardiac and brain tissue following recovery from neonatal CPR.
Aim: To compare the effects of vasopressin and epinephrine during resuscitation of asphyxiated post-transitional piglets on cardiac and brain tissue injury.
Horm Mol Biol Clin Investig
January 2025
Department of Biochemistry, Faculty of Medicine, 37555 Urmia University of Medical Sciences, Urmia, Iran.
Clin Exp Med
January 2025
Pediatrics, Western University, London, ON, Canada.
Sepsis is a major cause of morbidity and mortality worldwide. Among the various types of end-organ damage associated with sepsis, hepatic injury is linked to significantly higher mortality rates compared to dysfunction in other organ systems. This study aimed to investigate potential biomarkers of hepatic injury in sepsis patients through a multi-center, case-control approach.
View Article and Find Full Text PDFJ Clin Endocrinol Metab
January 2025
David Geffen School of Medicine at UCLA, University of California Los Angeles, Los Angeles, California.
Context: Little is known about presenting clinical characteristics, tumor biology, and surgical morbidity of Cushing's disease (CD) with aging.
Objective: Using a large multi-institutional dataset, we assessed diagnostic and prognostic significance of age in CD through differences in presentation, laboratory results, tumor characteristics, and postoperative outcomes.
Design: Data from the Registry of Adenomas of the Pituitary and Related Disorders (RAPID) were reviewed for patients with CD treated with transsphenoidal tumor resection at 11 centers between 2003 and 2023.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!